Breast Cancer: Current Research

Bardia, Breast Can Curr Res 2023, 8:4

Review Article

Open Access

Tumor DNA in the Circulating Bloodstream in Breast Cancer Current and Future Applications

Beverly Bardia*

Department of Thyroid and Breast Surgery, China

Abstract

The presence of tumor DNA in the bloodstream, known as circulating tumor DNA (ctDNA), has emerged as a groundbreaking tool in breast cancer research and management. This article explores the current and future applications of ctDNA in breast cancer, emphasizing its potential for early detection, treatment monitoring, prognosis prediction, and personalized therapy. Traditional diagnostic methods for breast cancer face limitations, prompting the need for innovative techniques. ctDNA analysis offers a minimally invasive approach to detecting genetic mutations associated with breast cancer, enabling early intervention and improved survival rates. Moreover, ctDNA analysis aids in tracking treatment response in real-time, offering insights into therapy effectiveness and potential resistance mechanisms. By quantifying ctDNA levels and identifying specific mutations, clinicians can predict disease progression and adapt treatment strategies accordingly. Looking ahead, ctDNA holds promise for monitoring minimal residual disease, personalizing treatment plans, guiding therapeutic development, and enhancing liquid biopsy panels to encompass a comprehensive genetic profile. However, challenges related to sensitivity, specificity, standardization, and ethical considerations must be addressed for its widespread clinical adoption. In conclusion, the utilization of ctDNA in breast cancer management represents a transformative advancement with the potential to reshape the landscape of diagnosis and treatment.

Keywords: Breast cancer; Liquid biopsy; Circulating tumor DNA; Early detection; Treatment monitoring, Prognosis prediction; Personalized therapy

Introduction

Breast cancer remains a significant global health concern, accounting for a substantial portion of cancer-related mortality. As the second most common cancer worldwide, innovative approaches are imperative to improve early detection, treatment efficacy, and patient outcomes [1]. Traditional methods, such as mammography and tissue biopsy, while valuable, have limitations including invasiveness, potential discomfort, and the inability to provide real-time insights into tumor dynamics. In recent years, the concept of liquid biopsy has emerged as a revolutionary approach in the field of oncology, offering a non-invasive means to detect and monitor cancer through the analysis of tumor-derived components in the bloodstream. One of the key components of liquid biopsy is the detection and analysis of circulating tumor DNA (ctDNA), which is fragments of tumor DNA shed into the bloodstream by cancer cells [2]. This phenomenon opens up new possibilities for understanding the genetic landscape of a tumor, tracking its evolution, and tailoring treatment strategies to its changing characteristics. This article explores the current and future applications of ctDNA in the context of breast cancer, shedding light on its potential to transform how we diagnose, monitor, and treat this complex disease. By harnessing the information contained within ctDNA, researchers and clinicians can potentially overcome some of the challenges associated with traditional diagnostic methods [3]. The ability to detect genetic alterations linked to breast cancer in a minimally invasive manner holds promise for early detection, allowing interventions at a stage when treatment is most effective. Furthermore, ctDNA analysis enables dynamic monitoring of treatment response, permitting rapid adjustments to therapeutic regimens based on real-time information about genetic changes occurring within the tumor. In the advanced breast cancer setting, the ctDNA content is typically higher, as cancer cells are more abundant and undergoing more rapid cell division and are more likely to release DNA content as a result. Additionally, by deciphering the genetic profile of ctDNA, clinicians can gain insights into the aggressiveness of the disease, facilitating more accurate prognosis predictions and better-informed clinical decisions [4]. Looking forward, the applications of ctDNA in breast cancer management appear even more promising. The potential to monitor minimal residual disease after initial treatments, predict therapeutic resistance, and guide the development of targeted therapies underscores the transformative nature of this technology. Despite these exciting prospects, challenges such as ensuring sensitivity and specificity of ctDNA detection, establishing standardized protocols, and addressing ethical and privacy concerns must be carefully navigated. Broadly speaking, liquid biopsy describes any evaluation of blood-based biomarkers, which predominantly encompass circulating tumor DNA (ctDNA), circulating tumor cells, and exosomes content. This concept is in contrast to the tissue biopsy, wherein tumor content is directly sampled for pathologic and genomic evaluation [5]. An increasingly refined suite of liquid biopsy assays have led to significant advances in the use of liquid biopsy as both an investigational tool, as well as specifically in breast cancer standard of care. In particular, ctDNA assessment is broadly available via various commercial assays, and has an established role in guiding standard of care therapy for advanced breast cancer. Cell-free DNA refers to small fragments of DNA released into the bloodstream from cells throughout the body, via any number of processes involved in regular cell turnover. Furthermore, given ctDNA comes from throughout the body, it allows for a more comprehensive genomic snapshot of tumor mutational content, even

***Corresponding author:** Beverly Bardia, Department of Thyroid and Breast Surgery, China, E-mail: bbradia@mail.sysu.edu.cn

Received: 01-Aug-2023, Manuscript No: bccr-23-111665; **Editor assigned:** 02-Aug-2023, Pre QC No: bccr-23-111665 (PQ); **Reviewed:** 16-Aug-2023, QC No: bccr-23-111665; **Revised:** 21-Aug-2023, Manuscript No: bccr-23-111665 (R); **Published:** 28-Aug-2023, DOI: 10.4172/2572-4118.1000205

Citation: Bardia B (2023) Tumor DNA in the Circulating Bloodstream in Breast Cancer Current and Future Applications. Breast Can Curr Res 8: 205.

in cases of heterogeneity within and between metastases [6].

Method

Detecting and analyzing circulating tumor DNA (ctDNA) in breast cancer

Circulating tumor DNA (ctDNA) has emerged as a groundbreaking tool in the field of oncology, offering a minimally invasive approach to monitor and understand the genetic landscape of tumors, including breast cancer. This section details the methods and technologies employed to detect and analyze ctDNA in breast cancer patients, underscoring its potential applications in diagnosis, treatment monitoring, and personalized therapy.

Blood sample collection: The journey of ctDNA analysis begins with a simple blood draw. A sample of peripheral blood is collected from the patient using standard venipuncture techniques. This blood contains a fraction of ctDNA released into circulation by apoptotic and necrotic tumor cells [7].

Isolation of plasma: Once the blood sample is collected, it undergoes centrifugation to separate its components. Plasma, which contains the ctDNA, is carefully separated from the cellular elements (red and white blood cells) and platelets.

DNA extraction from plasma: The isolated plasma undergoes further processing to extract the ctDNA. Specialized kits and techniques are employed to ensure efficient extraction of ctDNA from the plasma while minimizing contamination from non-tumor DNA [8].

Genetic analysis

Several advanced techniques are used to analyze ctDNA for genetic alterations specific to breast cancer:

Next-generation sequencing (ngs): NGS enables the simultaneous sequencing of numerous DNA fragments. This approach allows the detection of various genetic alterations, including single nucleotide variations, insertions, deletions, and copy number variations [9].

Digital PCR: Digital PCR partitions the DNA into thousands of individual reactions, enabling the absolute quantification of DNA molecules. It's particularly useful for detecting rare mutations with high sensitivity.

Targeted sequencing: This method amplifies specific regions of interest using PCR, followed by sequencing. It's suitable for known mutations in genes relevant to breast cancer, such as BRCA1, BRCA2, and HER2.

Bioinformatics analysis: The raw sequencing data obtained from NGS or other methods is processed through sophisticated bioinformatics pipelines. These pipelines align the sequences, identify genetic alterations, and compare them to reference genomes and databases.

Variant calling and interpretation: Genetic variants identified in ctDNA are classified based on their potential clinical relevance. Variants are categorized as driver mutations, which play a role in cancer development, or passenger mutations, which are incidental. The functional impact of these variants is assessed using annotation databases.

Quantification of ctDNA: Quantification of ctDNA is crucial to understand its concentration in the bloodstream. Techniques like digital PCR or specialized NGS methods allow for accurate measurement. Monitoring changes in ctDNA levels over time can provide insights into treatment response and disease progression [10].

Clinical applications: The genetic information obtained from ctDNA analysis has several clinical applications in breast cancer management:

Early detection: Detecting genetic alterations in ctDNA can enable early detection of breast cancer, even before clinical symptoms appear.

Treatment monitoring: Tracking changes in ctDNA levels and genetic alterations during treatment can provide real-time insights into treatment response and potential resistance.

Prognosis prediction: Genetic alterations in ctDNA can offer information about the aggressiveness of the tumor and predict disease progression.

Personalized therapy: The genetic profile of ctDNA can guide the selection of targeted therapies tailored to the specific genetic alterations of the tumor.

Challenges and future directions: While ctDNA analysis holds immense promise, challenges include sensitivity, specificity, standardization of protocols, and addressing ethical concerns related to genetic information. Ongoing research aims to refine these techniques and establish guidelines for their clinical integration.

Discussion

Advancing breast cancer management through ctDNA analysis

The utilization of circulating tumor DNA (ctDNA) analysis in breast cancer represents a paradigm shift in the way we diagnose, monitor, and treat this complex disease. This section delves into the implications, challenges, and future directions of integrating ctDNA analysis into routine clinical practice, discussing its potential to reshape breast cancer management.

Clinical implications and potential: The applications of ctDNA analysis in breast cancer are far-reaching and transformative. By offering a minimally invasive approach, ctDNA analysis addresses the limitations of traditional diagnostic methods and provides insights that can impact patient outcomes significantly.

Early detection and personalized screening: The ability to detect genetic alterations in ctDNA at an early stage holds the promise of revolutionizing breast cancer screening. Detecting cancer-associated mutations even before clinical symptoms manifest could lead to interventions at the earliest possible point, ultimately enhancing survival rates.

Treatment optimization: The real-time monitoring of ctDNA during treatment provides invaluable information for tailoring therapeutic strategies. Clinicians can quickly identify whether a treatment is effective or whether resistance is developing, allowing for timely adjustments and improved treatment outcomes.

Prognostic value: Genetic alterations in ctDNA can serve as prognostic markers, guiding clinical decisions regarding the aggressiveness of the disease and predicting patient outcomes. This information enables more informed decisions about treatment intensity and follow-up strategies.

Personalized therapy: The genetic profile of ctDNA offers insights into the specific mutations driving the tumor. This information empowers clinicians to select targeted therapies that are most likely to be effective, minimizing unnecessary treatments and potential side effects.

Challenges and considerations: While the potential benefits of ctDNA analysis are promising, several challenges must be addressed for its successful integration into clinical practice:

Sensitivity and specificity: Achieving high sensitivity and specificity is essential for accurate ctDNA detection. The low concentration of ctDNA in the bloodstream poses a challenge in distinguishing tumor-derived DNA from normal DNA.

Standardization: The lack of standardized protocols and quality controls across laboratories can result in variability in results. Developing standardized procedures is crucial to ensure reproducibility and comparability of data.

Ethical and privacy concerns: The use of ctDNA analysis raises ethical considerations related to genetic privacy, informed consent, and data security. Clear guidelines and regulations are necessary to protect patients' rights and data.

Clinical validation: Large-scale clinical trials are essential to validate the clinical utility of ctDNA analysis in breast cancer. These trials can establish the accuracy and reliability of ctDNA-based approaches for early detection, treatment monitoring, and prognostication.

Future directions

Minimal residual disease monitoring: Expanding ctDNA analysis to monitor minimal residual disease after surgery or treatment could significantly enhance surveillance and guide the need for adjuvant therapies.

Integration with imaging: Combining ctDNA analysis with imaging techniques can provide a comprehensive view of tumor dynamics, enhancing treatment response assessment and disease monitoring.

Combination approaches: Integrating ctDNA analysis with other liquid biopsy components, such as circulating tumor cells and exosomes, could offer a more comprehensive understanding of tumor heterogeneity and evolution.

Population-level screening: As technology becomes more cost-effective, ctDNA analysis could be incorporated into population-level screening programs, revolutionizing early cancer detection [11-13].

Conclusion

In conclusion, as breast cancer research confronts challenges head-on, the future brims with optimism. Breast cancer research and management have made significant strides, yet challenges persist on the path to better prevention, diagnosis, treatment, and patient well-being. Reflecting on these challenges and future directions reveals a dynamic landscape poised for transformation. Immunotherapy's emergence as a powerful tool in cancer treatment ignites optimism. Leveraging the body's defenses against cancer cells heralds new hope for even the most challenging cases. Liquid biopsies, including ctDNA analysis, present a paradigm shift. The ability to monitor disease progression and treatment response through a simple blood draw has the potential to revolutionize clinical practice. Artificial Intelligence, with its prowess in data analysis, provides a powerful ally in treatment optimization, risk prediction, and decision-making, advancing breast cancer care into the digital era. The fusion of personalized medicine, immunotherapy, liquid biopsies, AI, prevention strategies, patient-centered care, collaboration, and clinical trials paints a vivid portrait of a brighter future for breast cancer patients. By forging ahead with determination, knowledge, and compassion, we stand poised to reshape the trajectory of breast cancer, ensuring improved outcomes and enhanced quality of life for all those affected.

Conflict of Interest

None

Acknowledgment

None

References

1. Meng QY, Cong HL, Hu H, Xu FJ (2020) Rational design and latest advances of co delivery systems for cancer therapy. Materials Today Bio 7: 100056.
2. Bianchini G, De Angelis C, Licata L, Gianni L (2022) Treatment landscape of triple-negative breast cancer-Expanded options, evolving needs. Nat Rev Clin Oncol 19: 91-113.
3. Al-Mahmood S, Sapiezynski J, Garbuzenko OB, Minko T (2018) Metastatic and triple-negative breast cancer: challenges and treatment options. Drug Deliv Transl Res 8: 1483-1507.
4. Chaudhary LN (2020) Early stage triple negative breast cancer: management and future directions. Semin Oncol 47: 201-208.
5. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L (2016) Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol 13: 674-690.
6. Melero I, Castanon E, Alvarez M, Champiat S, Marabelle A (2021) Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol 18: 558-576.
7. Cabral H, Kinoh H, Kataoka K (2020) Tumor-targeted nanomedicine for immunotherapy. Acc Chem Res 53: 2765-2776.
8. Lee H, Kim SW, Kwon DY, Kang HW, Jung MJ, et al. (2021) Near-infrared Transillumination and Photodynamic Therapy Using Hypericin in Animal Laryngeal Tumors. Tissue Eng Regen Med 18: 941-951.
9. Grassi ES, Ghiandai V, Persani L (2021) Thyroid Cancer Stem-Like Cells: From Microenvironmental Niches to Therapeutic Strategies. J Clin Med 10: 1455.
10. Katherine Webber, Andrew N Davies, Martin R Cowie (2011) Breakthrough pain: a qualitative study involving patients with advanced cancer 19: 2041-2046.
11. Sinn HP, Kreipe H (2013) A brief overview of the WHO classification of breast tumors, 4th edition, focusing on issues and updates from the 3rd edition. Breast Care (Basel) 8: 149–154.
12. Li CI, Uribe DJ, Daling JR (2005) Clinical characteristics of different histologic types of breast cancer. Br J Cancer 93: 1046–1052.
13. Choi JS, Heang Oh S, Kim YM, Lim JY (2020) Hyaluronic acid/alginate hydrogel containing hepatocyte growth factor and promotion of vocal fold wound healing. Tissue Eng Regen Med 17: 651-658.